Skip to main content
PMC home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1996 Apr;80(4):292–296. doi: 10.1136/bjo.80.4.292

Progression of disease in ocular cicatricial pemphigoid.

M J Elder 1, W Bernauer 1, J Leonard 1, J K Dart 1
PMCID: PMC505451  PMID: 8703876

Abstract

BACKGROUND: Ocular cicatricial pemphigoid (OCP) is a sight threatening autoimmune disease that can lead to severe conjunctival cicatrisation and keratopathy. It has a variable course and little is known about the factors that determine disease progression. This study analysed the factors that have prognostic significance regarding disease outcome, progression, and keratopathy. METHODS: Sixty six patients with OCP were monitored prospectively at Moorfields Eye Hospital. The influence of ocular features, the systemic disease, and the management were analysed to identify factors that influence the outcomes and disease progression. RESULTS: The mean age at presentation was 67 years; 56% were men. The binocular visual acuities were 6/24 or worse in 25%. Extensive cicatrisation at presentation was common but correlated only weakly with the visual prognosis. Systemic manifestations included lesions of the mouth in 44%, pharynx in 30%, oesophagus in 27%, nose/sinus in 18%, and skin in 17%. There was no association between the ocular and systemic manifestations. Persistent corneal epithelial defects and limbitis occurred in 18% and 32%, respectively, and both were associated with a worse visual prognosis. Systemic immunosuppression was ultimately prescribed in 74%, mainly in patients with advanced stages of conjunctival cicatrisation. Of patients with more than 24 months follow up, progression of cicatrisation occurred in 35% of eyes (16/46) all but one of which were associated with episodes of conjunctival inflammation. CONCLUSIONS: Persistent epithelial defects, limbal inflammation, and ongoing conjunctival inflammation are important factors that lead to keratopathy and visual handicap. These require aggressive management, often with systemic immunosuppressive treatment. Close follow up is required in cases with extensive cicatrisation.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bernauer W., Wright P., Dart J. K., Leonard J. N., Lightman S. The conjunctiva in acute and chronic mucous membrane pemphigoid. An immunohistochemical analysis. Ophthalmology. 1993 Mar;100(3):339–346. doi: 10.1016/s0161-6420(93)31644-1. [DOI] [PubMed] [Google Scholar]
  2. Elder M. J., Lightman S., Dart J. K. Role of cyclophosphamide and high dose steroid in ocular cicatricial pemphigoid. Br J Ophthalmol. 1995 Mar;79(3):264–266. doi: 10.1136/bjo.79.3.264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Foster C. S. Cicatricial pemphigoid. Trans Am Ophthalmol Soc. 1986;84:527–663. [PMC free article] [PubMed] [Google Scholar]
  4. Foster C. S., Wilson L. A., Ekins M. B. Immunosuppressive therapy for progressive ocular cicatricial pemphigoid. Ophthalmology. 1982 Apr;89(4):340–353. doi: 10.1016/s0161-6420(82)34791-0. [DOI] [PubMed] [Google Scholar]
  5. Hardy K. M., Perry H. O., Pingree G. C., Kirby T. J., Jr Benign mucous membrane pemphigoid. Arch Dermatol. 1971 Nov;104(5):467–475. [PubMed] [Google Scholar]
  6. Leonard J. N., Hobday C. M., Haffenden G. P., Griffiths C. E., Powles A. V., Wright P., Fry L. Immunofluorescent studies in ocular cicatricial pemphigoid. Br J Dermatol. 1988 Feb;118(2):209–217. doi: 10.1111/j.1365-2133.1988.tb01776.x. [DOI] [PubMed] [Google Scholar]
  7. Lever W. F. Pemphigus and pemphigoid. A review of the advances made since 1964. J Am Acad Dermatol. 1979 Jul;1(1):2–31. doi: 10.1016/s0190-9622(79)80050-x. [DOI] [PubMed] [Google Scholar]
  8. Mondino B. J., Brown S. I. Immunosuppressive therapy in ocular cicatricial pemphigoid. Am J Ophthalmol. 1983 Oct;96(4):453–459. doi: 10.1016/s0002-9394(14)77908-5. [DOI] [PubMed] [Google Scholar]
  9. Mondino B. J., Brown S. I. Ocular cicatricial pemphigoid. Ophthalmology. 1981 Feb;88(2):95–100. doi: 10.1016/s0161-6420(81)35069-6. [DOI] [PubMed] [Google Scholar]
  10. Mondino B. J. Cicatricial pemphigoid and erythema multiforme. Ophthalmology. 1990 Jul;97(7):939–952. doi: 10.1016/s0161-6420(90)32479-x. [DOI] [PubMed] [Google Scholar]
  11. Mondino B. J., Ross A. N., Rabin B. S., Brown S. I. Autoimmune phenomena in ocular cicatricial pemphigoid. Am J Ophthalmol. 1977 Apr;83(4):443–450. doi: 10.1016/0002-9394(77)90546-3. [DOI] [PubMed] [Google Scholar]
  12. Ormerod L. D., Fong L. P., Foster C. S. Corneal infection in mucosal scarring disorders and Sjögren's syndrome. Am J Ophthalmol. 1988 May 15;105(5):512–518. doi: 10.1016/0002-9394(88)90243-7. [DOI] [PubMed] [Google Scholar]
  13. Rice B. A., Foster C. S. Immunopathology of cicatricial pemphigoid affecting the conjunctiva. Ophthalmology. 1990 Nov;97(11):1476–1483. doi: 10.1016/s0161-6420(90)32402-8. [DOI] [PubMed] [Google Scholar]
  14. Sacks E. H., Jakobiec F. A., Wieczorek R., Donnenfeld E., Perry H., Knowles D. M., Jr Immunophenotypic analysis of the inflammatory infiltrate in ocular cicatricial pemphigoid. Further evidence for a T cell-mediated disease. Ophthalmology. 1989 Feb;96(2):236–243. doi: 10.1016/s0161-6420(89)32922-8. [DOI] [PubMed] [Google Scholar]
  15. Schwab I. R., Linberg J. V., Gioia V. M., Benson W. H., Chao G. M. Foreshortening of the inferior conjunctival fornix associated with chronic glaucoma medications. Ophthalmology. 1992 Feb;99(2):197–202. doi: 10.1016/s0161-6420(92)32001-9. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES